Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Annovis Bio, Inc. (ANVS)

Annovis Bio estimates $2.8 million in cash as of September 30, 2026, unaudited

Neutral Impact 3 of 5 earnings Written later

Annovis Bio said in a preliminary, unaudited estimate that it had approximately $2.8 million in cash and cash equivalents as of September 30, 2026. The company has not finished its quarterly closing process, and its auditor has not reviewed the figure, so the final results may differ.

Key points

  • Estimated cash and cash equivalents: approximately $2.8 million as of September 30, 2026
  • Interim financial statements for the three and nine months ended September 30, 2026 are not yet available
  • Independent registered public accounting firm has not reviewed or expressed an opinion on the estimates

The filing

CompanyAnnovis Bio, Inc. (ANVS)
Form8-K, current report
Filed with the SECNov 4, 2026, 4:06 PM ET
Accession number0001104659-26-122665

Items reported: 2.02 Results of Operations7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 04, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.